The results depicted in Fig. 6l demonstrate that, compared to the PBS and ADV-Ctr treated groups, the ADV-ApoA1 treated group exhibited a higher presence of immune cells in the tumor microenvironment. This evidence concerns the gene APOA1 and neoplasm.